Department of Pharmacy, Uppsala University, Box 580, 751 23 Uppsala, Sweden.
Wendelsbergs beräkningskemi AB, Kyrkvägen 7B, 435 35 Mölnlycke, Sweden.
Eur J Pharm Biopharm. 2018 Dec;133:70-76. doi: 10.1016/j.ejpb.2018.10.006. Epub 2018 Oct 6.
Particle size reduction is a traditional approach to increase the intestinal absorption of active pharmaceutical ingredients with poor intestinal solubility, by increasing the particle dissolution rate. However, an increase in the dissolution rate cannot always fully explain the effects of nanoformulations, and a method of assessing the potential benefits of a nanoformulation in vivo would hence be of great value in drug development. A novel mathematical model of a nanoformulation, including interlinked descriptions of the hydrodynamics, particle dissolution and diffusion of particles and colloidal structures (CS), was developed to predict the combined in vivo effects of these mechanisms on drug absorption. The model successfully described previously reported in vivo observations of nanoformulated aprepitant in rats, at various drug concentrations and in the presence or absence of CS. The increase in absorption rate was explained as a direct consequence of the increased drug concentration at the membrane, caused by the contributing effects of the diffusion of both nanoparticles and CS into which the drug had partitioned. Further simulations supported the conclusion that the model can be applied during drug development to provide a priori assessments of the potential benefits of nanoformulations.
粒径减小是一种传统的方法,可以通过增加粒子的溶解速率来提高肠道溶解度差的活性药物成分的肠道吸收。然而,溶解速率的增加并不总能完全解释纳米制剂的作用,因此,一种评估纳米制剂体内潜在益处的方法在药物开发中具有重要价值。本文开发了一种纳米制剂的新数学模型,包括对流体动力学、粒子溶解以及粒子和胶体结构(CS)扩散的相互关联的描述,以预测这些机制对药物吸收的综合体内效应。该模型成功地描述了以前报道的在不同药物浓度下以及存在或不存在 CS 的情况下,纳米制剂阿瑞匹坦在大鼠体内的观察结果。吸收速率的增加被解释为由于药物分配到其中的纳米粒子和 CS 的扩散,导致膜上药物浓度增加的直接结果。进一步的模拟支持了这样的结论,即该模型可以在药物开发过程中应用,以预先评估纳米制剂的潜在益处。